This section contains information to help providers bill for clinical laboratory tests or examinations related to molecular pathology and diagnostic services.

### Molecular Pathology Code Chart

The chart included later in this section correlates molecular pathology CPT® and HCPCS Level II codes with the following:

- Treatment Authorization Request (TAR) and claim documentation requirements
- Allowable diagnosis (ICD-10-CM) codes
- Once-in-a-lifetime and other frequency limitations for reimbursement
- Select modifier and split-billing information

**Note:** Policy for most molecular pathology codes fits within the chart; however, some policy was too lengthy or complex for the chart and is covered outside of the chart.

### Modifiers

For a description of the modifiers billed with certain codes, refer to the *Modifiers: Approved List* section in this manual.
## Tier 1, Molecular Pathology, Code Correlation Chart

Providers should refer to the CPT code book for full descriptions of the following codes.

<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81120 IDH1 (isocitrate dehydrogenase 1 [NADP^+], soluble), common variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): C71.0 – C71.9 or C92.00 – C92.02</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81121 IDH2 (isocitrate dehydrogenase 2 [NADP^+], mitochondrial), common variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): C71.0 – C71.9 or C92.00 – C92.02</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81161 DMD (dystrophin) deletion analysis, and duplication analysis, if performed</td>
<td>No</td>
<td>ICD-10-CM diagnosis code G71.0 (muscular dystrophy) is required on the claim.</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| 81162, BRCA1, BRCA2 gene analysis; full sequence analysis and full duplication/deletion analysis | Yes | A TAR for CPT code 81162 requires documentation of one or more of the following numbered criteria.

1. Based on 2019 U.S. Preventive Services Task Force (USPSTF) recommendation:
   - The patient has personal or family history that suggests an inherited cancer susceptibility based on any one of the following familial risk assessment tools:
     - The Ontario Family History Assessment Tool
     - Manchester Scoring System
     - Referral Screening Tool
     - Pedigree Assessment Tool
     - 7-Question Family History Screening Tool
     - International Breast Cancer Intervention Study instrument
     - Brief versions of BRCAPRO; AND
   - The patient is willing to talk with a health professional who is suitably trained to provide genetic counseling and interpret test results; AND
   - The test results will aid in the decision-making; OR

2. An individual from a family member with a known deleterious BRCA mutation; OR

(continued on next page)

* See end of code 81162 listing for more information
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81162                | Yes          | 3. Personal history of breast cancer (invasive or ductal carcinoma in situ) plus one or more of the following:  
  • Diagnosed at ≤45 years of age; OR  
  • Diagnosed at 46–50 years of age with:  
    – An additional breast cancer primary at any age  
    – One or more close blood relatives with breast cancer at any age  
    – One or more close blood relatives with prostate cancer (Gleason score ≥7)  
    – An unknown or limited family history; OR  
  • Diagnosed at ≤60 years of age with a triple negative breast cancer; OR  
  • Diagnosed at any age with:  
    – One or more close blood relatives with:  
      a. Breast cancer diagnosed at ≤50 years of age; or  
      b. Ovarian carcinoma; or  
      c. Male breast cancer; or  
      d. Metastatic prostate cancer; or  
      e. Pancreatic cancer  
    – Two or more additional diagnosis of breast cancer at any age in patient and/or in close blood relatives; OR  
  • Ashkenazi Jewish ancestry; OR  
|                      |              | 4. Personal history of ovarian carcinoma (includes fallopian tube and primary peritoneal cancers); OR  
|                      |              | 5. Personal history of male breast cancer; OR  
|                      |              | 6. Personal history of pancreatic cancer; OR  
|                      |              | 7. Personal history of metastatic prostate cancer (biopsy-proven and/or with radiographic evidence; includes distant metastasis and regional bed or nodes; not biochemical recurrence); OR  |

*(continued on next page)*
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81162</td>
<td>Yes</td>
<td>8. Personal history of high-grade prostate cancer (Gleason score ≥7) at any age with:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• One or more close blood relatives (first-, second- or third-degree) with ovarian carcinoma, pancreatic cancer or metastatic prostate cancer at any age or breast cancer under 50 years of age; or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Two or more close blood relatives (first-, second- or third-degree relatives on the same side of family) with breast or prostate cancer (any grade) at any age; or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Ashkenazi Jewish ancestry; OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9. BRCA1/2 pathogenic/likely pathogenic variant detected by tumor profiling on any tumor type in the absence of germline pathogenic/likely pathogenic variant analysis; OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10. For an individual without history of breast or ovarian cancer, but with one or more first- or second-degree blood relative meeting any of the above criteria; OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11. For BRACAnalysis CDx testing for breast cancer, all of the following TAR criteria must be met:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patient has metastatic breast cancer.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patient is human epidermal growth factor receptor 2 (HER2)-negative.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patient has previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patient's additional treatment is contingent on the test results.</td>
<td></td>
</tr>
</tbody>
</table>

* An approved TAR that meets the necessary criteria listed below to override the once-in-a-lifetime frequency is required:

For patients with previous BRCA test other than BRACAnalysis CDx, repeat BRCA testing with BRACAnalysis CDx may be necessary when treatment with Lynparza™ (olaparib) is contingent on the test results.
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81163 BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) gene analysis; full sequence analysis</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>81164 BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) gene analysis; full duplication/deletion analysis</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>81165 BRCA1 (BRCA1, DNA repair associated) gene analysis; full sequence analysis</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>81166 BRCA1 (BRCA1, DNA repair associated) gene analysis; full duplication/deletion analysis</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>81167 BRCA2 (BRCA2, DNA repair associated) gene analysis; full duplication/deletion analysis</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>81170 ALB1 gene analysis, variants in the kinase domain</td>
<td>Yes</td>
<td>Requires documentation on the TAR that the recipient has chronic myeloid leukemia (CML) and failed tyrosine kinase inhibitor (TKI) therapy</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>81171 AFF2 (AF4/FMR2 family, member 2 [FMR2]) gene analysis evaluation to detect abnormal alleles</td>
<td>No</td>
<td>One of the following ICD-10-CM diagnosis codes is required on the claim (except with valid TAR): F70, F71, F80.0 – F89, H93.25, R48.0, R62.0 – R62.59, F82, F88, R48.2</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>81172 AFF2 (AF4/FMR2 family, member 2 [FMR2]) gene analysis; characterization of alleles</td>
<td>No</td>
<td>One of the following ICD-10-CM diagnosis codes is required on the claim (except with valid TAR): F70, F71, F80.0 – F89, H93.25, R48.0, R62.0 – R62.59, F82, F88, R48.2</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>81173 AR (androgen receptor) gene analysis; full gene sequence</td>
<td>Yes</td>
<td>A TAR for CPT code 81173 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient has clinical signs or symptoms suspicious for bulbar muscular atrophy, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient requires the service as a confirmatory test for spinal and bulbar muscular atrophy</td>
<td></td>
</tr>
<tr>
<td>81174 AR (androgen receptor) gene analysis; known familial variant</td>
<td>Yes</td>
<td>A TAR for CPT code 81174 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient has clinical signs or symptoms suspicious for bulbar muscular atrophy, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient requires the service as a confirmatory test for spinal and bulbar muscular atrophy</td>
<td></td>
</tr>
<tr>
<td>81175 ASXL gene analysis, full gene sequence</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR):</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C93.10 – C93.12, D46.0 – D46.C, D47.1</td>
<td></td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>----------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>81176 ASXL gene analysis, targeted sequence analysis</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): C93.10 – C93.12, D46.0 – D46.C, D47.1</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81177 ATN1 (atrophin 1) gene analysis, evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81177 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for dentatorubral pallidoluysian atrophy, and • The patient requires the service as a confirmatory test for dentatorubral pallidoluysian atrophy</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>81178 ATXN1 (ataxin 1) gene analysis, evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81178 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 1 (SCA1), and • The patient requires the service as a confirmatory test for SCA1</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>81179 ATXN2 (ataxin 2) gene analysis, evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81179 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 2 (SCA2), and • The patient requires the service as a confirmatory test for SCA2</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>81180 ATXN3 (ataxin 3) gene analysis, evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81180 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 3 (SCA3), and • The patient requires the service as a confirmatory test for SCA3</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 81181  ATXN7 (ataxin 7) gene analysis, evaluation to detect abnormal alleles         | Yes          | A TAR for CPT code 81181 requires documentation of the following criteria:  
  - The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 7 (SCA7), and  
  - The patient requires the service as a confirmatory test for SCA7  
|                                                                                      |              |                                                                                                              | Once-in-a-lifetime except with valid TAR override                          |
| 81182  ATXN8OS (ATXN8 opposite strand [non-protein coding]) gene analysis, evaluation to detect abnormal alleles | Yes          | A TAR for CPT code 81182 requires documentation of the following criteria:  
  - The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 8 (SCA8), and  
  - The patient requires the service as a confirmatory test for SCA8  
|                                                                                      |              |                                                                                                              | Once-in-a-lifetime except with valid TAR override                          |
| 81183  ATXN10 (ataxin 10) gene analysis, evaluation to detect abnormal alleles       | Yes          | A TAR for CPT code 81183 requires documentation of the following criteria:  
  - The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 10 (SCA10), and  
  - The patient requires the service as a confirmatory test for SCA10  
|                                                                                      |              |                                                                                                              | Once-in-a-lifetime except with valid TAR override                          |
| 81184  CACNA1A (calcium voltage-gated channel subunit alpha1 A) gene analysis; evaluation to detect abnormal alleles | Yes          | A TAR for CPT code 81184 requires documentation of the following criteria:  
  - The patient has clinical signs or symptoms suspicious for Episodic ataxia type 2 (EA2), and  
  - The patient requires the service as a confirmatory test for EA2  
|                                                                                      |              |                                                                                                              | Once-in-a-lifetime except with valid TAR override                          |
| 81185  CACNA1A (calcium voltage-gated channel subunit alpha1 A) gene analysis; full gene sequence | Yes          | A TAR for CPT code 81185 requires documentation of the following criteria:  
  - The patient has clinical signs or symptoms suspicious for Episodic ataxia type 2 (EA2), and  
  - The patient requires the service as a confirmatory test for EA2  
<p>|                                                                                      |              |                                                                                                              | Once-in-a-lifetime except with valid TAR override                          |</p>
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81186    | CACNA1A (calcium voltage-gated channel subunit alpha1 A) gene analysis; known familial variant | Yes          | A TAR for CPT code 81186 requires documentation of the following criteria:  
• The patient has clinical signs or symptoms suspicious for Episodic ataxia type 2 (EA2), and  
• The patient requires the service as a confirmatory test for EA2  
Once-in-a-lifetime except with valid TAR override |                                  |
| 81187    | CNBP (CCHC-type zinc finger nucleic acid binding protein) gene analysis; evaluation to detect abnormal alleles | Yes          | A TAR for CPT code 81187 requires documentation of the following criteria:  
• The patient has clinical signs or symptoms suspicious for Myotonic dystrophy type 2 (MD2), and  
• The patient requires the service as a confirmatory test for MD2  
Once-in-a-lifetime except with valid TAR override |                                  |
| 81188    | CSTB (cystatin B) gene analysis; evaluation to detect abnormal alleles       | Yes          | A TAR for CPT code 81188 requires documentation of the following criteria:  
• The patient has clinical signs or symptoms suspicious for myoclonic epilepsy type 1 and requires the service as a confirmatory test for myoclonic epilepsy type 1, and  
• Treatment will be contingent on test results  
Once-in-a-lifetime except with valid TAR override |                                  |
| 81189    | CSTB (cystatin B) gene analysis; full gene sequence                          | Yes          | A TAR for CPT code 81189 requires documentation of the following criteria:  
• The patient has clinical signs or symptoms suspicious for myoclonic epilepsy type 1 and requires the service as a confirmatory test for myoclonic epilepsy type 1, and  
• Treatment will be contingent on test results  
Once-in-a-lifetime except with valid TAR override |                                  |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81190 CSTB (cystatin B) gene analysis; known familial variant(s) | Yes | A TAR for CPT code 81190 requires documentation of the following criteria:  
- The patient has clinical signs or symptoms suspicious for myoclonic epilepsy type 1 and requires the service as a confirmatory test for myoclonic epilepsy type 1, and  
- Treatment will be contingent on test results | Once-in-a-lifetime except with valid TAR override |
| 81201 APC gene analysis; full gene sequence | No | One of the following ICD-10-CM codes is required on the claim: C18.0 – C18.9, D12.0 – D12.9, K63.5, Z86.010 | Once-in-a-lifetime |
| 81202 APC gene analysis; known familial variants | Yes | Requires documentation on the TAR of a family history of familial adenomatous polyposis that includes a relative with a known deleterious APC mutation | Once-in-a-lifetime |
| 81203 APC gene analysis; duplication/deletion variants | No | One of the following ICD-10-CM codes is required on the claim: C18.0 – C18.9, D12.0 – D12.9, K63.5, Z86.010 | Once-in-a-lifetime |
| 81204 AR (androgen receptor) gene analysis; characterization of alleles | Yes | A TAR for CPT code 81204 requires documentation of the following criteria:  
- The patient has clinical signs or symptoms suspicious for bulbar muscular atrophy, and  
- The patient requires the service as a confirmatory test for spinal and bulbar muscular atrophy | Once-in-a-lifetime except with valid TAR override |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81206 BCR/ABL1 translocation analysis; major breakpoint</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C91.00 – C91.02 or C92.10 – C92.12</td>
<td>N/A</td>
</tr>
<tr>
<td>81207 BCR/ABL1 translocation analysis; minor breakpoint</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C91.00 – C91.02 or C92.10 – C92.12</td>
<td>N/A</td>
</tr>
<tr>
<td>81208 BCR/ABL1 translocation analysis; other breakpoint</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C91.00 – C91.02 or C92.10 – C92.12</td>
<td>N/A</td>
</tr>
<tr>
<td>81210 BRAF (B-Raf proto-oncogene, serine/threonine kinase), gene analysis, V600 variant(s)</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C18.0 – C18.9, C19, C20, <strong>C33, C34.00 – C34.92</strong>, C43.0 – C43.9, C79.2 or D03.0 – D03.9</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81212 BRCA1, BRCA2 gene analysis; variants</td>
<td>Yes</td>
<td>Requires documentation on the TAR of the following: • An individual is of an ethnicity associated with the Ashkenazi Jewish population No additional family history may be required</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CPT Code</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>81215</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>BRCA1 (breast cancer 1) gene analysis; known familial variant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81216</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>BRCA2 (breast cancer 2) gene analysis; full sequence analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81217</td>
<td>Yes</td>
<td>See CPT code 81162 for TAR criteria and billing requirements.</td>
<td>See CPT code 81162</td>
</tr>
<tr>
<td>BRCA2 (breast cancer 2) gene analysis; known familial variant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81218</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C92.00 – C92.02, C92.40 – C92.42 or C92.50 – C92.52</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) gene analysis, full gene sequence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>81219</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C92.10 – C92.12, D45, D47.3 or D75.81</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CALR (calreticulin) gene analysis, common variants in exon 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants</td>
<td>No</td>
<td>When used to bill for cystic-fibrosis screening requires ICD-10-CM diagnosis code <strong>009.00 – 009.93, Z31.430, Z31.440, Z34.00 – Z34.03, Z34.80 – Z34.83, Z34.90 – Z34.93</strong> Not reimbursable with code 81224 for same date of service, recipient and provider May be billed separately with an appropriate National Correct Coding Initiative (NCCI) associated modifier Refer to the <em>Genetic Counseling and Screening</em> section for additional information</td>
<td>Once-in-a-lifetime</td>
</tr>
</tbody>
</table>
| 81221 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants | Yes | TAR requires documentation of the following criteria:  
  - The Patient has a strong clinical presentation suspicious of CF, and  
  - Family with known variant not included in the test for common variants | Once-in-a-lifetime |
| 81222 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants | Yes | TAR requires a documentation of the following criteria:  
  - The patient has a strong clinical presentation suspicious of CF, and  
  - Gene test for common variants did not result in two disease-causing variants in CFTR | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81223 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence | Yes | TAR requires documentation of the following criteria:  
- Patient has intermediate sweat chloride result, or  
- Patient with confirmed or suspected CF, with unknown genotype, and additional treatment or assessment of prognosis is contingent on the result of the test, or  
- Patient with normal sweat chloride results despite a strong clinical suspicion of CF | Once-in-a-lifetime |
| 81224 CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility) | No | When used to bill for cystic-fibrosis testing requires ICD-10-CM diagnosis code N46.9 | Once-in-a-lifetime |
| 81225 CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19), gene analysis, common variants | No | One of the following ICD-10-CM diagnosis codes is required on the claim (except with valid TAR): I21.01 – I24.9 | Once-in-a-lifetime except with valid TAR override |
| 81233 BTK (Bruton's tyrosine kinase) gene analysis, common variants | No | One of the following ICD-10-CM codes is required on the claim (except with valid TAR): D80.0 – D80.6, C91.10 – C91.12, C83.00 – C83.09 | Once-in-a-lifetime except with valid TAR override |
| 81234 DMPK (DM1 protein kinase) gene analysis; evaluation to detect abnormal alleles | Yes | A TAR for CPT code 81234 requires documentation of the following criteria:  
- The patient has clinical signs or symptoms suspicious for myotonic dystrophy type 1 (MD1), and  
- The patient requires the service as a diagnostic test for MD1. | Once-in-a-lifetime except with valid TAR override |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81235 EGFR (epidermal growth factor receptor) gene analysis, common variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C33, C34.00 – C34.92</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81236 EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) gene analysis, full gene sequence</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): D47.1, D47.3, C83.30 – C83.39</td>
<td>N/A</td>
</tr>
<tr>
<td>81237 EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) gene analysis, common variant(s)</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): D47.1, D47.3, C83.30 – C83.39</td>
<td>N/A</td>
</tr>
<tr>
<td>81238 F9 (coagulation factor IX) full gene analysis sequence</td>
<td>No</td>
<td>ICD-10-CM code D67 is required on the claim (except with valid TAR)</td>
<td>Once-in-a-lifetime</td>
</tr>
</tbody>
</table>
| 81239 DMPK (DM1 protein kinase) gene analysis; characterization of alleles | Yes | A TAR for CPT code 81239 requires documentation of the following criteria:  
- The patient has clinical signs or symptoms suspicious for myotonic dystrophy type 1 (MD1), and  
- The patient requires the service as a diagnostic test for MD1. | Once-in-a-lifetime except with valid TAR override |
<p>| 81243 FMR1 (fragile X mental retardation 1) gene analysis; evaluation to detect abnormal alleles | No | One of the following ICD-10-CM codes is required on the claim: F70, F71 – F73, F78, F80.0 – F84.2, F88, F89, H93.25, R48.2, R62.0, R62.50 – R62.59 | Once-in-a-lifetime |</p>
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81244 FMR1 (fragile X mental retardation 1) gene analysis; characterization of alleles</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: F70, F71 – F73, F78, F80.0 – F84.2, F88, F89, H93.25, R48.2, R62.0, R62.50 – R62.59</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81245 FLT3 (fms-related tyrosine kinase 3), gene analysis; internal tandem duplication (ITD) variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C92.00 – C92.02, C92.60 – C92.62 or C92.A0 – C92.A2</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81246 FLT3 (fms-related tyrosine kinase 3), gene analysis; tyrosine kinase domain (TKD) variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C92.00 – C92.02, C92.60 – C92.62 or C92.A0 – C92.A2</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81250 G6PC (glucose-6-phosphatase, catalytic subunit) gene analysis, common variants</td>
<td>Yes</td>
<td>The patient has clinical features suspicious for, or requires the laboratory service as a diagnostic test for glycogen storage disease, type 1a</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81256 HFE (hemochromatosis) gene analysis, common variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: E83.10, E83.110 or E83.118 – E83.119</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81257 HBA1/HBA2 (alpha globin 1 and alpha globin 2), gene analysis; common deletions or variant</td>
<td>No</td>
<td>N/A</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>----------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>81258 HBA1/HBA2 (alpha globin 1 and alpha globin 2), gene analysis; known familial variant</td>
<td>No</td>
<td>N/A</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81259 HBA1/HBA2 (alpha globin 1 and alpha globin 2), gene analysis; full gene sequence</td>
<td>No</td>
<td>N/A</td>
<td>Once-in-a-lifetime</td>
</tr>
</tbody>
</table>
| 81260 IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinas complex-associated protein) gene analysis, common variants | Yes | Requires documentation on the TAR of:  
- Hypotonia in infancy  
- Decreased or absent deep tendon reflexes  
- Decreased taste and absence of fungiform papillae of the tongue  
- Absence of overflow tears with emotional crying (alacrima)  
- Absence of axon flare response after intradermal histamine injection  
- Pupillary hypersensitivity to parasympathomimetic agents | Once-in-a-lifetime |
<p>| 81265 Comparative analysis using Short Tandem Repeat markers | No | One of the following ICD-10-CM codes is required on the claim: C81.00 – C96.9, D45, T86.00 – T86.09 or T86.5 | Once-in-a-lifetime |
| 81266 Comparative analysis using Short Tandem Repeat markers; each additional specimen | No | One of the following ICD-10-CM codes is required on the claim: C81.00 – C96.9, D45, T86.00 – T86.09 or T86.5 | Once-in-a-lifetime |
| 81267 Chimerism (engraftment) analysis, post transplantation specimen; without cell selection | No | One of the following ICD-10-CM codes is required on the claim: T86.01, T86.02, T86.09 or T86.5 | N/A |</p>
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81268 Chimerism (engraftment) analysis, post transplantation specimen; with cell selection</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: T86.01, T86.02, T86.09 or T86.5</td>
<td>N/A</td>
</tr>
<tr>
<td>81269 HBA1/HBA2 (alpha globin 1 and alpha globin 2), gene analysis; duplication/deletion variants</td>
<td>No</td>
<td>N/A</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81270 JAK2 (Janus kinase 2) gene analysis, p. Val617Phe (V617F) variant</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C91.00 – C91.02, D45, D47.1 or D47.3</td>
<td>Once-in-a-lifetime</td>
</tr>
</tbody>
</table>
| 81271 HTT (huntingtin) gene analysis; evaluation to detect abnormal alleles | Yes | A TAR for CPT code 81271 requires documentation of the following criteria:  
  - For adults, the patient has unequivocal motor signs of Huntington’s disease (HD) and requires the service to confirm the diagnosis  
  - For children, the patient has a family history of HD and develops symptoms that raise the suspicion for juvenile-onset HD as exemplified by two or more of the following:  
    - Declining school performance  
    - Seizures  
    - Oral motor dysfunction  
    - Rigidity  
    - Gait disturbance | Once-in-a-lifetime except with valid TAR override |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81272 KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), gene analysis, targeted sequence analysis</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C43.70, C92.00 – C92.02, C92.40 – C92.42, C92.50 – C92.52, D03.70 – D03.72 or D48.1</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81273 KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), gene analysis, D816 variant(s)</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C96.20 – C96.29</td>
<td>Once-in-a-lifetime</td>
</tr>
</tbody>
</table>
| 81274 HTT (huntingtin) gene analysis; characterization of alleles | Yes | A TAR for CPT code 81274 requires documentation of the following criteria:  
- For adults, the patient has unequivocal motor signs of Huntington’s disease (HD) and requires the service to confirm the diagnosis  
- For children, the patient has a family history of HD and develops symptoms that raise the suspicion for juvenile-onset HD as exemplified by two or more of the following:  
  - Declining school performance  
  - Seizures  
  - Oral motor dysfunction  
  - Rigidity  
  - Gait disturbance | Once-in-a-lifetime except with valid TAR override |
<p>| 81275 KRAS (Kirsten rat sarcoma viral oncogene homolog) gene analysis; variants in exon 2 | No | One of the following ICD-10-CM codes is required on the claim: C18.0 – C20, D01.1, D01.2, D01.40, D01.49, D37.4 or D37.5 | Once-in-a-lifetime |</p>
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRAS (Kristen rat sarcoma viral oncogene homolog) gene analysis; additional variant(s)</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C18.0, C18.2 – C20, D01.1, D01.2, D01.40, D01.49, D37.4 or D37.5</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>IFNL3 (interferon, lambda 3), gene analysis, rs12979860 variant</td>
<td>No</td>
<td>ICD-10-CM code B18.2 is required on the claim (except with valid TAR)</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>FXN (frataxin) gene analysis; evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81284 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for Friedreich ataxia (FRDA), and • The patient requires the service as a confirmatory test for FRDA</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>FXN (frataxin) gene analysis; characterization of alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81285 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for Friedreich ataxia (FRDA), and • The patient requires the service as a confirmatory test for FRDA</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>FXN (frataxin) gene analysis; full gene sequence</td>
<td>Yes</td>
<td>A TAR for CPT code 81286 requires documentation of the following criteria: • The patient has clinical signs or symptoms suspicious for Friedreich ataxia (FRDA), and • The patient requires the service as a confirmatory test for FRDA</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>MGMT (O-6 methylguanin-DNA methyltransferase) methylation analysis</td>
<td>Yes</td>
<td>Document on the TAR: • The patient has the diagnosis of glioblastoma multiforme, and • Treatment strategy will be contingent on the test results</td>
<td>Once-in-a-lifetime, any provider</td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>
| 81288 | MLH1 gene analysis; promoter methylation analysis | Yes | Document the following criteria on the TAR:  
- Patient with colon cancer, and  
- The tumor demonstrates microsatellite instability or immunohistochemistry results indicating loss of MLH1 protein expression | Once-in-a-lifetime |
| 81289 | FXN (frataxin) gene analysis; known familial variant(s) | Yes | **A TAR for CPT code 81289 requires documentation of the following criteria:**  
- The patient has clinical signs or symptoms suspicious for Friedreich ataxia (FRDA), and  
- The patient requires the service as a confirmatory test for FRDA | Once-in-a-lifetime except with valid TAR override |
| 81292 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) gene analysis; full sequence analysis | No | One of the following ICD-10-CM codes is required on the claim:  
C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9,  
C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9,  
Z80.0, Z80.49, Z85.030, Z85.038, Z85.040,  
Z85.048, Z85.42 | Once-in-a-lifetime |
| 81293 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) gene analysis; known familial variants | Yes | Document on the TAR family history of Lynch Syndrome that includes a relative with a known deleterious MLH1 mutation | Once-in-a-lifetime |
| 81294 | MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) gene analysis; duplication/deletion variants | No | One of the following ICD-10-CM codes is required on the claim:  
C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9,  
C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9,  
Z80.0, Z80.49, Z85.030, Z85.038, Z85.040,  
Z85.048, Z85.42 | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81295 MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) gene analysis; full sequence analysis</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81296 MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) gene analysis; known familial variants</td>
<td>Yes</td>
<td>Document on the TAR family history of Lynch Syndrome that includes a relative with a known deleterious MSH2 mutation</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>81297</td>
<td>MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) gene analysis; duplication/deletion variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42</td>
</tr>
<tr>
<td>81298</td>
<td>MSH6 (mutS homolog 6 [E. coli]) gene analysis; full sequence analysis</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42</td>
</tr>
<tr>
<td>81299</td>
<td>MSH6 (mutS homolog 6 [E. coli]) gene analysis; known familial variants</td>
<td>Yes</td>
<td>Document on the TAR family history of Lynch Syndrome that includes a relative with a known deleterious MSH6 mutation</td>
</tr>
<tr>
<td>81300</td>
<td>MSH6 (mutS homolog 6 [E. coli]) gene analysis; duplication/deletion variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42</td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>81301</td>
<td>Microsatellite instability analysis of markers for mismatch repair deficiency, includes comparison of neoplastic and normal tissue, if performed</td>
<td>No</td>
<td>Reimbursable for patients who meet one of the following criteria: the patient is diagnosed with one of the Lynch syndrome-associated cancers; or, the patient is diagnosed with an unresectable or metastatic solid tumor and the treatment will be contingent on the test result.</td>
</tr>
<tr>
<td>81305</td>
<td>MYD88 (myeloid differentiation primary response 88) (gene analysis, p.Leu265Pro (L265P) variant</td>
<td>No</td>
<td>The following ICD-10-CM code is required on the claim (except with valid TAR): C88.0</td>
</tr>
<tr>
<td>81306</td>
<td>NUDT15 (nudix hydrolase 15) gene analysis, common variant(s)</td>
<td>Yes</td>
<td>A TAR for CPT code 81306 requires documentation of the following criteria: - The patient is undergoing thiopurine therapy, and - The patient has severe or prolonged myelosuppression.</td>
</tr>
<tr>
<td>81310</td>
<td>NPM1 (nucleophosmin) gene analysis, exon 12 variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C92.00 – C92.02</td>
</tr>
<tr>
<td>81311</td>
<td>NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) gene analysis, variants in exon 2 and exon 3</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C18.0, C18.2 – C20, D01.1, D01.2, D01.40, D01.49, D37.4 or D37.5</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| 81312 PABPN1 (poly[A] binding protein nuclear 1) gene analysis, evaluation to detect abnormal alleles | Yes | A TAR for CPT code 81312 requires documentation of the following criteria:  
- The patient has symptoms of ptosis and dysphagia, and  
- The patient requires the service as a confirmatory test for Oculopharyngeal Muscular Dystrophy | Once-in-a-lifetime except with valid TAR override |
| 81314 PDGFRA (platelet-derived growth factor receptor, alpha polypeptide), gene analysis, targeted sequence analysis | No | ICD-10-CM code D48.1 is required on the claim. | Once-in-a-lifetime |
| 81315 PML/RAR-alpha (promyelocytic leukemia/retinoic acid receptor alpha) translocation analysis; common breakpoints | No | One of the following ICD-10-CM codes is required on the claim:  
C92.40 – C92.42 | N/A |
| 81316 PML/RAR-alpha (promyelocytic leukemia/retinoic acid receptor alpha) translocation analysis; single breakpoint | No | One of the following ICD-10-CM codes is required on the claim:  
C92.40 – C92.42 | N/A |
| 81317 PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) gene analysis; full sequence analysis | No | One of the following ICD-10-CM codes is required on the claim:  
C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42 | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81318 PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) gene analysis; known familial variants</td>
<td>Yes</td>
<td>Document on the TAR family history of Lynch Syndrome that includes a relative with a known deleterious PMS2 mutation</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81319 PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) gene analysis; duplication/deletion variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030, Z85.038, Z85.040, Z85.048, Z85.42</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81320 PLCG2 (phospholipase C gamma 2) gene analysis, common variants</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): C91.10 – C91.12</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| 81321 PTEN (phosphatase and tensin homolog) gene analysis; full sequence analysis | Yes | A TAR for CPT code 81321 requires documentation of one or more of the following numbered criteria:  
1. Individual with a personal history of:  
   - Bannayan-Riley-Ruvalcaba syndrome, or  
   - Adult Lhermitte-Duclos disease, or  
   - Autism spectrum disorder AND macrocephaly, or  
   - Two or more biopsy-proven trichilemmomas, or  
   - Two or more major criteria (one macrocephaly), or  
   - Three major criteria without macrocephaly, or  
   - One major and three or more minor criteria, or  
   - Four or more minor criteria (please see list below)  
2. At-risk individual:  
   With a relative who has a clinical diagnosis of Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome for whom testing has not been performed AND who has any one major criterion or two minor criteria | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81321 PTEN gene analysis; full sequence analysis (continued) | Yes | Major Criteria  
• Breast cancer  
• Mucocutaneous lesions  
• One biopsy-proven trichilemmoma  
• Multiple palmoplantar keratosis  
• Multifocal or extensive oral mucosal papillomatosis  
• Multiple cutaneous facial papules (often verrucous)  
• Macular pigmentation of glans penis  
• Macroencephaly (megalocephaly, ie, ≥97th percentile)  
• Endometrial cancer  
• Non-medullary thyroid cancer  
• Multiple GI tract hamartomas or ganglioneuromas  
Minor Criteria  
• Other thyroid lesions (adenoma, nodule, goiter)  
• Mental retardation (IQ ≤75)  
• Autism spectrum disorder  
• Single GI tract hamartoma or ganglioneuroma  
• Fibrocystic disease of the breast  
• Lipomas  
• Fibromas  
• Renal cell carcinoma  
• Uterine fibroids | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81322 PTEN gene analysis; known familial variant</td>
<td>Yes</td>
<td>Requires documentation on the TAR that patient is from a family with a known PTEN mutation</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81323 PTEN gene analysis; duplication/deletion variant</td>
<td>Yes</td>
<td>Requires documentation on the TAR of a negative result in the full sequence analysis in PTEN (CPT code 81321), and that patient meets one or more criteria listed under code 81321</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81329 SMN1 (survival of motor neuron 1, telomeric) gene analysis; dosage/deletion analysis, includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed</td>
<td>No</td>
<td>One of the following ICD-10-CM diagnosis codes is required on the claim (except with valid TAR): O09.00 – O09.93, Z31.430, Z31.440, Z34.00 – Z34.03, Z34.80 – Z34.83, Z34.90 – Z34.93,</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
</tbody>
</table>
| 81331 SNRPN/UBE3A methylation analysis | Yes | Document the following age-specific criteria on the TAR  
- **Birth to 2 years**: Hypotonia with poor suck  
- **2 – 6 years**: Hypotonia with history of poor suck and global development delay  
- **6 – 13 years**: History of hypotonia with poor suck (hypotonia often persists); global development delay; and excessive eating (hyperphagia; obsession with food) with central obesity if uncontrolled  
- **13 years – adult**: Cognitive impairment – usually mild mental retardation; excessive eating (hyperphagia; obsession with food) with central obesity if uncontrolled; and hypothalamic hypogonadism and/or typical behavior problems (including temper tantrums and obsessive-compulsive features) | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81334</td>
<td>RUNX1 (runt related transcription factor 1), gene analysis, targeted sequence analysis</td>
<td>No</td>
<td>One of the following ICD-10-CM codes is required on the claim (except with valid TAR): C92.00 – C92.02, C92.40 – C92.A2</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81335</td>
<td>TPMT (thiopurine S-methyltransferase), gene analysis, common variants</td>
<td>Yes</td>
<td>The service requires a TAR with documentation of the following criteria:</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• That the patient is undergoing thiopurine therapy, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient has severe or prolonged myelosuppression.</td>
<td></td>
</tr>
<tr>
<td>81336</td>
<td>SMN1 (survival of motor neuron 1, telomeric) gene analysis; full gene sequence</td>
<td>Yes</td>
<td>A TAR for CPT code 81336 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient has clinical signs or symptoms suspicious for spinal muscular atrophy, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient requires the service as a confirmatory test for spinal muscular atrophy</td>
<td></td>
</tr>
<tr>
<td>81337</td>
<td>SMN1 (survival of motor neuron 1, telomeric) gene analysis; known familial sequence variant(s)</td>
<td>Yes</td>
<td>A TAR for CPT code 81337 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient has clinical signs or symptoms suspicious for spinal muscular atrophy, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient requires the service as a confirmatory test for spinal muscular atrophy</td>
<td></td>
</tr>
<tr>
<td>81343</td>
<td>PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) gene analysis, evaluation to detect abnormal alleles</td>
<td>Yes</td>
<td>A TAR for CPT code 81343 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 12 (SCA12), and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The patient requires the service as a confirmatory test for SCA12</td>
<td></td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| 81344    | TBP (TATA box binding protein) gene analysis, evaluation to detect abnormal alleles | Yes | A TAR for CPT code 81344 requires documentation of the following criteria:  
• The patient has clinical signs or symptoms suspicious for spinocerebellar ataxia type 17 (SCA17), and  
• The patient requires the service as a confirmatory test for SCA17 | Once-in-a-lifetime except with valid TAR override |
| 81345    | TERT (telomerase reverse transcriptase) gene analysis, targeted sequence analysis | Yes | Document the following criteria on the TAR:  
• The patient has the diagnosis of grade II, III or IV glioma. | Once-in-a-lifetime except with valid TAR override |
| 81361    | HBB (hemoglobin, subunit beta); common variant(s) (eg, HbS, HbC, HbE) | No | N/A | Once-in-a-lifetime |
| 81362    | HBB (hemoglobin, subunit beta); known familial variant(s) | No | N/A | Once-in-a-lifetime |
| 81363    | HBB (hemoglobin, subunit beta); duplication/deletion variant(s) | No | N/A | Once-in-a-lifetime |
| 81364    | HBB (hemoglobin, subunit beta); full gene sequence | No | N/A | Once-in-a-lifetime |
### Human Platelet Antigen Genotyping ICD-10-CM Diagnosis Codes

When billing for the following Tier 1 Molecular Pathology CPT codes, ICD-10-CM diagnosis codes D69.51 and P61.0 are required:

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>81105</th>
<th>81109</th>
</tr>
</thead>
<tbody>
<tr>
<td>81106</td>
<td>81110</td>
<td></td>
</tr>
<tr>
<td>81107</td>
<td>81111</td>
<td></td>
</tr>
<tr>
<td>81108</td>
<td>81112</td>
<td></td>
</tr>
</tbody>
</table>

### Tier 2, Molecular Pathology Procedure, Level 1

Coverage for CPT code 81400 (molecular pathology procedure, Level 1) is limited to the listed services. Reimbursement for code 81400 requires an approved *Treatment Authorization Request* (TAR), is limited to once in a lifetime and requires providers to document one of the following on the TAR:

- **CCR5** (chemokine C-C motif receptor 5):
  - Initial test:
    - The use of a CCR5 inhibitor is being considered, or
    - The patient exhibits virologic failure on a CCR5 inhibitor
  - Subsequent tests:
    - A previous Trofile test was performed including the test date and the results showing that the patient has a CCR5 virus, and,
    - The patient’s previous Trofile test was not less than 90 days from subsequent request, and,
    - The patient has clinical scenario such as, but not limited to the following:
      - The treatment with CCR5 antagonist drug therapy was interrupted and the clinician wishes to reinstitute CCR5 antagonist drug therapy, or,
      - The patient had a Trofile test performed previously that showed that the patient had the CCR5 virus, but the CCR5 antagonist drug therapy was never initiated.
Coverage for CPT code 81401 (molecular pathology procedure, Level 2) is limited to the listed services. Reimbursement for code 81401 requires an approved TAR and requires providers to document one of the following on the TAR:

- **ABCC8 (familial hyperinsulinism):**
  - The patient has persistent hyperinsulinemic hypoglycemia of infancy (PHHI), failed medical therapy, and
  - The patient is under evaluation for surgical intervention
- **ABL (c-abl oncogene 1, receptor tyrosine kinase) – The patient has chronic myeloid leukemia (CML) and failed tyrosine kinase inhibitor (TKI) therapy**
- **ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance), T315I variant – The patient has chronic myeloid leukemia (CML) and failed tyrosine kinase inhibitor (TKI) therapy**
- **DEK/NUP214 (t [6; 9])(eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed – The patient has acute myeloid leukemia and the test is intended for the process of risk stratification**
- **E2A/PBX1 (acute lymphocytic leukemia):**
  - The patient has the diagnosis of acute lymphocytic/lymphoblastic leukemia, and
  - Treatment or monitoring strategy will be contingent on the test results
- **ETV6/RUNX1 (acute lymphocytic leukemia) – The patient has the diagnosis of acute lymphocytic or lymphoblastic leukemia, and requires the test for assessment of cancer prognosis**
- **H19 (Beckwith-Wiedemann syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Beckwith-Wiedemann syndrome**
- **KCNO1OT1 (Beckwith-Wiedemann syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Beckwith-Wiedemann syndrome**
- **LINC00518 (long intergenic non-protein coding RNA 518):**
  - The patient has diagnosis of melanoma, and
  - The treatment strategy will be contingent on test results
• MLL/AFF1 (acute lymphoblastic leukemia):
  - The patient has the diagnosis of acute lymphoblastic leukemia, and
  - Treatment or monitoring strategy will be contingent on the test results
• MLL/MLLT3 (acute myeloid leukemia):
  - The patient has the diagnosis of acute myeloid leukemia, and
  - Treatment or monitoring strategy will be contingent on the test results
• MUTYH (MYH-associated polyposis) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for MUTYH-associated polyposis
• MT-ATP6 (neuropathy with ataxia and retinitis pigmentosa [NARP], Leigh syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for NARP or Leigh syndrome
• PRAME (preferentially expressed antigen in melanoma):
  - The patient has diagnosis of melanoma, and
  - The treatment strategy will be contingent on the test results
• PRSS1 (hereditary pancreatitis):
  - An unexplained documented episode of acute pancreatitis in childhood, or
  - Recurrent acute attacks of pancreatitis of unknown cause, or
  - Chronic pancreatitis of unknown cause, particularly with onset younger than 25 years of age, or
  - A family history of recurrent acute pancreatitis, chronic pancreatitis of unknown cause, and/or childhood pancreatitis of unknown cause consistent with autosomal dominant inheritance
• PYGM (glycogen storage disease type V, McArdle disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glycogen storage disease type V (McArdle disease)
• RUNX1/RUNX1T1 (t[8;21]) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for acute myeloid leukemia
Tier 2, Molecular Pathology Procedure, Level 3

Coverage for CPT code 81402 (molecular pathology procedure, Level 3) is limited to the listed services. Reimbursement for code 81402 requires an approved TAR and requires providers to document one of the following on the TAR:

- Chromosome 1p-/19q- (e.g. gliial tumors), deletion analysis –
- Patient with diagnosis of grade II, III or IV glioma

Tier 2, Molecular Pathology Procedure, Level 4

Coverage for CPT code 81403 (molecular pathology procedure, Level 4) is limited to the listed services. Reimbursement for code 81403 requires an approved TAR and requires providers to document one of the following on the TAR:

- DNMT3A (acute myeloid leukemia):
  - The patient has diagnosis of acute myeloid leukemia, and
  - The treatment strategy will be contingent on test results
- EPCAM (Lynch syndrome) – The patient has one of the following:
  - Colon cancer
  - Uterine cancer
  - Lynch syndrome
  - Family history of colorectal cancer, uterine cancer or Lynch syndrome
  - Presence of synchronous, metachronous colorectal or other Lynch-associated tumors
• JAK 2 (Janus kinase 2) – The patient has clinical features suspicious for, or requires the service as a diagnostic test for myeloproliferative disorder

• KCNC3 (spinocerebellar ataxia) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for spinocerebellar ataxia

• KCNJ11 (familial hyperinsulinism) – TAR may be approved based on one of the following criteria:
  – For persistent hyperinsulinemic hypoglycemia of infancy (PHHI):
    ❖ The patient has PHHI and failed medical therapy, and
    ❖ The patient is under evaluation for surgical intervention
  – For suspected developmental delay, epilepsy and neonatal diabetes (DEND) syndrome:
    ❖ The patient has developmental delay, epilepsy and neonatal diabetes
    ❖ The confirmation of the diagnosis and the treatment strategy is contingent on the test result

• KIR (killer cell immunoglobulin-like receptor for hematopoietic stem cell transplantation):
  – The patient has diagnosis of acute myeloid leukemia or multiple myeloma, and
  – The test is used for donor search process for patients considering hematopoietic stem cell transplantation

• Known family variant not otherwise specified, for gene listed in Tier 1 or Tier 2, or identified during a genomic sequencing procedure (GSP), DNA sequence analysis, each variant exon:
  – Documentation of the specific gene listed in Tier 1, Tier 2 or GSP for which further analysis is being requested

• MICA (solid organ transplantation):
  – The patient is undergoing evaluation for kidney transplantation, or
  – The patient is post kidney transplantation

• MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) – The patient has clinical features suspicious for, or requires the service as a diagnostic test for myeloproliferative disorder
• NDP (Norrie disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Norrie disease

• SH2D1A (X-linked lymphoproliferative syndrome) – The patient is a male with the diagnosis of:
  – Common variable immune deficiency, or
  – Hypogammaglobulinemia, or
  – Hemophagocytic lymphohistiocytosis, or
  – Severe infectious mononucleosis, or
  – Lymphoma, or
  – Family history of X-linked lymphoproliferative syndrome

• VHL (von Hippel-Lindau tumor suppressor), deletion/duplication analysis – The patient has clinical features suspicious for, or requires the service as a diagnostic test for von Hippel-Lindau syndrome
Tier 2, Molecular Pathology Procedure, Level 5

Coverage for CPT code 81404 (molecular pathology procedure, Level 5) is limited to the listed services. Reimbursement for code 81404 requires an approved Treatment Authorization Request (TAR) and requires providers to document one of the following on the TAR:

- ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain), targeted sequence analysis:
  - The patient has elevated C4-C on newborn screening test, and
  - Confirmation (urine acylglycines or urine organic acids) that C4 (butyrylcarnitine) and/or ethylmalonic acid (EMA) are elevated
- CD40LG (X-linked hyper IgM syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for hyperimmunoglobulin M syndromes
- EMD (Emery-Dreifuss muscular dystrophy) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Emery-Dreifuss muscular dystrophy
- EPM2A (progressive myoclonus epilepsy) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for progressive myoclonus epilepsy
- FHL1 (Emery-Dreifuss muscular dystrophy) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Emery-Dreifuss muscular dystrophy
- NDP (Norrie disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Norrie disease
- PDX1 (pancreatic and duodenal homeobox 1)
  - The patient requires the service as a diagnostic test for (maturity onset diabetes of the young) MODY, and
  - Is younger than 25 years of age, and
  - Has a family history of diabetes, and
  - Has negative islet of autoantibodies
- PRNP (genetic prion disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for genetic prion disease

- PRSS1 (hereditary pancreatitis):
  - An unexplained documented episode of acute pancreatitis in childhood, or
  - Recurrent acute attacks of pancreatitis of unknown cause, or
  - Chronic pancreatitis of unknown cause, particularly with onset younger than 25 years of age, or
  - A family history of recurrent acute pancreatitis, chronic pancreatitis of unknown cause, and/or childhood pancreatitis of unknown cause consistent with autosomal dominant inheritance

- RET (ret proto-oncogen), common variants
  - The patient has a personal history of primary C cell hyperplasia, Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine Neoplasia (MEN), type 2B, or
  - The patient has a family history consistent with MEN, type 2B or MTC, and at risk for autosomal dominant inheritance of the syndrome

- SH2D1A (X-linked lymphoproliferative syndrome) – The patient is a male with the diagnosis of:
  - Common variable immune deficiency, or
  - Hypogammaglobulinemia, or
  - Hemophagocytic lymphohistiocytosis, or
  - Severe infectious mononucleosis, or
  - Lymphoma, or
  - Family history of X-linked lymphoproliferative syndrome
• SPINK1 (hereditary pancreatitis):
  − An unexplained documented episode of acute pancreatitis in childhood, or
  − Recurrent acute attacks of pancreatitis of unknown cause, or
  − Chronic pancreatitis of unknown cause, particularly with onset younger than 25 years of age, or
  − A family history of recurrent acute pancreatitis, chronic pancreatitis of unknown cause, and/or childhood pancreatitis of unknown cause consistent with autosomal dominant inheritance

• TP53 (tumor protein 53, targeted sequence analysis of 2 – 5 exons). Coverage is reimbursable for one of the following numbered criteria:

1) All of the following conditions:
  − The patient has sarcoma diagnosed before 45 years of age, and
  − A first-degree relative with any cancer before 45 years of age, and
  − A first or second-degree relative with any cancer before 45 years of age, or a sarcoma at any age; or

2) All of the following conditions:
  − A tumor belonging to the Li-Fraumeni Syndrome (LFS) tumor spectrum (soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenocortical carcinoma, leukemia or lung bronchoalveolar cancer) before 46 years of age, and
  − At least one first or second-degree relative with an LFS tumor (except breast cancer if the patient has breast cancer) before 56 years of age or with multiple tumors; or

3) The patient has multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum, and the first occurred before 46 years of age; or

4) The patient is diagnosed with adrenocortical carcinoma or choroid plexus tumor.
Tier 2, Molecular Pathology Procedure, Level 6

Coverage for CPT code 81405 (molecular pathology procedure, level 6) is limited to the listed services. Reimbursement for code 81405 requires an approved TAR and requires providers to document one of the following on the TAR:

- **ABCD1** (adrenoleukodystrophy):
  - The patient has clinical features suspicious for adrenoleukodystrophy, and
  - Measurement of plasma concentration of very long chain fatty acids (VLCFA) is inconclusive, and
  - The service is required as a confirmatory test for the diagnosis of adrenoleukodystrophy

- **ACADS** (acyl-CoA dehydrogenase, C-2 to C-3 short chain), full gene sequence:
  - The patient has elevated C4-C on newborn screening test, and
  - Confirmation (urine acylglycines or urine organic acids) that C4 (butyrylcarnitine) and/or ethylmalonic acid (EMA) are elevated

- **CPOX** (coproporphyrinogen oxidase), full gene sequence:
  - The patient has elevated urinary and fecal coproporphyrin III, and
  - The patient requires the service as a confirmatory test for hereditary coproporphyria

- **EMD** (Emery-Dreifuss muscular dystrophy) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Emery-Dreifuss muscular dystrophy

- **GLA** (galactosidase alpha [for example, Fabry disease]), full gene sequence:
  - The patient has a family member with documented disease-causing mutation, and
  - The decision whether to initiate enzyme replacement therapy will be contingent on the results
• HNF1A (HNF1 homeobox A)
  – The patient requires the service as a diagnostic test for MODY, and
  – Is younger than 25 years of age, and
  – Has a family history of diabetes, and
  – Has negative islet of autoantibodies

• HNF1B (HNF1 homeobox B)
  – The patient requires the service as a diagnostic test for MODY, and
  – Is younger than 25 years of age, and
  – Has a family history of diabetes, and
  – Has negative islet of autoantibodies

• LAMP2 (Danon disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glycogen storage disease IIb (Danon disease)

• NF2 (neurofibromatosis, type 2):
  – The patient has clinical features suspicious for, or requires the service as a confirmatory test for type 2 neurofibromatosis, OR
  – The patient is at high risk for neurofibromatosis with one or more of the following:
    ◆ A first-degree relative with type 2 neurofibromatosis
    ◆ Multiple spinal tumors (schwannomas, meningiomas)
    ◆ Cutaneous schwannomas
    ◆ Sporadic vestibular schwannoma younger than 30 years of age, or spinal tumor or meningioma younger than 20 years of age
• **NPHS2** (steroid resistant nephrotic syndrome [SRNS])
  - The patient has clinical diagnosis of SRNS, and
  - Treatment will be contingent on the test results

• **OTC** (ornithine transcarbamylase deficiency) – The patient has clinical signs and symptoms of urea cycle disorders with positive biochemical laboratory results and requires the service as a confirmatory test for ornithine transcarbamylase deficiency

• **PKLR** (pyruvate kinase, liver and RBC), full gene sequence – The patient has clinical features suspicious for, or requires the service as a confirmatory test for pyruvate kinase deficiency

• **RET** (multiple endocrine neoplasia [MEN], type 2A and familial medullary thyroid carcinoma [MTC]) – exons 10, 11, 13 – 16:
  - The patient has a personal history of MTC, or MEN, type 2A, or
  - The patient has pheochromocytoma and a family history of MTC or pheochromocytoma, or
  - The patient has sporadic MEN2-related tumors and is younger than 35 years of age, multicentric tumors in one organ, and/or two different organs affected, or
  - The patient has a family history consistent with MEN, type 2A

• **RET** (ret proto-oncogen), targeted sequence analysis:
  - The patient has a personal history of primary C cell hyperplasie, MTC, or MEN, type 2A, or
  - The patient has a family history consistent with MEN, type 2A or MTC, and at risk for autosomal dominant inheritance of the syndrome

• **SLC2A1** (glucose transporter type 1 [GLUT 1] deficiency syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for GLUT 1 deficiency syndrome
• SPRED1 (Legius syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Legius syndrome

• TCF4 (Pitt-Hopkins syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Pitt-Hopkins syndrome

• TP53 (tumor protein 53 targeted sequence analysis of 2 – 5 exons): Coverage is reimbursable for one of the following numbered criteria:

1) All of the following conditions:
   - The patient has sarcoma diagnosed before 45 years of age, and
   - A first-degree relative with any cancer before 45 years of age, and
   - A first or second-degree relative with any cancer before 45 years of age, or a sarcoma at any age; or

2) All of the following conditions:
   - A tumor belonging to the Li-Fraumeni Syndrome (LFS) tumor spectrum (soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenocortical carcinoma, leukemia or lung bronchoalveolar cancer) before 46 years of age, and
   - At least one first or second-degree relative with an LFS tumor (except breast cancer if the patient has breast cancer) before 56 years of age or with multiple tumors; or

3) The patient has multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum, and the first occurred before 46 years of age; or

4) The patient is diagnosed with adrenocortical carcinoma or choroid plexus tumor.

• TSC1 (tuberous sclerosis complex 1) – duplication/deletion analysis – The patient has signs or symptoms of tuberous sclerosis complex but a diagnosis cannot be clinically confirmed

• WT1 (Wilms tumor 1) – full gene sequence – The patient has suspected or confirmed acute myeloid leukemia, and the result of the test will influence the diagnosis, prognosis and/or therapeutic management
Tier 2, Molecular Pathology Procedure, Level 7

Coverage for CPT code 81406 (molecular pathology procedure, Level 7) is limited to the listed services. Reimbursement for code 81406 requires an approved TAR and requires providers to document one of the following on the TAR:

- ACADVL (very long chain acyl-coenzyme A dehydrogenase deficiency) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for ACADVL
- AFG3L2 (spinocerebellar ataxia) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for spinocerebellar ataxia
- ATP7B (Wilson disease):
  - The patient has clinical features suspicious for Wilson disease, and
  - Diagnosis cannot be made based on the results of biochemical testing and liver biopsy, and
  - The patient requires the service as a confirmatory test for Wilson disease
- BTK (X-linked agammaglobulinemia):
  - The male patient has clinical features suspicious for X-linked agammaglobulinemia, and
  - The male patient has less than two percent CD19+ B cells
• CDH1 (hereditary diffuse gastric cancer):
  − Two gastric cancer cases in family, one confirmed diffuse gastric cancer younger than 50 years of age, or
  − Three confirmed diffuse gastric cancer cases in first or second degree relatives, regardless of age, or
  − Diffuse gastric cancer diagnosed younger than 40 years of age, or
  − Personal or family history of diffuse gastric cancer and lobular breast cancer, one diagnosed younger than 50 years of age

• CNTNAP2 (Pitt-Hopkins-like syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Pitt-Hopkins syndrome
• GCK (glucokinase [hexokinase 4])
  – The patient requires the service as a diagnostic test for MODY, and
  – Is younger than 25 years of age, and
  – Has a family history of diabetes, and
  – Has negative islet of autoantibodies

• GLUD1 (familial hyperinsulinism):
  – The patient has persistent hyperinsulinemic hypoglycemia of infancy (PHHI) and failed medical therapy, and
  – The patient is under evaluation for surgical intervention

• HMBS (hydroxymethylbilane synthase), full gene sequence – The patient has clinical features suspicious for, or requires the service as a confirmatory test for acute intermittent porphyria

• HNF4A (hepatocyte nuclear factor 4, alpha)
  – The patient requires the service as a diagnostic test for MODY, and
  – Is younger than 25 years of age, and
  – Has a family history of diabetes, and
  – Has negative islet of autoantibodies
• JAG1 (Alagille syndrome) – duplication/deletion – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Alagille syndrome

• KCNQ2 (potassium voltage-gated channel, KQT-like subfamily, member 2 [eg, epileptic encephalopathy], full gene sequence)
  – The patient has clinical symptoms and electroencephalogram (EEG) patterns consistent with early infantile epileptic encephalopathy, and
  – Treatment is contingent on test results

• MUTYH (MYH-associated polyposis) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for MUTYH-associated polyposis

• NF2 (neurofibromatosis, type 2):
  – The patient has clinical features suspicious for, or requires the service as a confirmatory test for type 2 neurofibromatosis, or
  – The patient is at high risk for neurofibromatosis with one or more of the following:
    ❖ A first-degree relative with type 2 neurofibromatosis
    ❖ Multiple spinal tumors (schwannomas, meningiomas)
    ❖ Cutaneous schwannomas
    ❖ Sporadic vestibular schwannoma younger than 30 years of age, or spinal tumor or meningioma younger than 20 years of age
• PCSK9 (proprotein convertase subtilisin/kexin type 9) (eg, familial hypercholesterolemia), full gene sequence
  – Patient has coronary artery disease (CAD) or has risk factors for CAD
  – The intention to treat or not to treat with PCSK9 inhibitors will be contingent, at least in part, on the test results

• PHEX (phosphate-regulating endopeptidase homolog, X-Linked) (eg, hypophosphatemic rickets), full gene sequence
  1. The patient is undergoing evaluation for X-Linked Hypophosphatemia (XLH); and
  2. Diagnosis was not able to be established based on biochemical testing, which included the following tests:
     – Serum calcium, phosphate and alkaline phosphatase, and
     – PTH, 25 hydroxyvitamin D, and 1,25 dihydroxyvitamin D, and
     – Urinary calcium excretion; and
  3. The confirmation of the diagnosis and the treatment strategy is contingent on the test result.
- POLG (polymerase [DNA directed], gamma [eg, Alpers-Huttenlocher syndrome, autosomal dominant progressive external ophthalmoplegia], full gene sequence). TAR may be approved based on one of the following numbered criteria:
  - The patient is undergoing consideration for treatment using valproic acid, or
  - The patient is undergoing evaluation for potentially having any one of the following conditions:
    - Alpers-Huttenlocher syndrome
    - Ataxia neuropathy spectrum (ANS), previously known as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy, dysarthria and ophthalmoplegia (SANDO)
    - Autosomal dominant progressive external ophthalmoplegia
    - Autosomal recessive progressive external ophthalmoplegia
    - Childhood myocerebrohepatopathy spectrum
    - Myoclonic epilepsy myopathy sensory ataxia
- PPOX (protoporphyrinogen oxidase), full gene sequence – The patient has clinical features suspicious for, or requires the service as a confirmatory test for acute variegate porphyria
- PRKCG (spinocerebellar ataxia) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for spinocerebellar ataxia
- PYGM (glycogen storage disease type V, McArdle disease) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glycogen storage disease type V (McArdle disease)
• RPE65 (retinal pigment epithelium-specific protein 65kDa)
  – Patient has a clinical diagnosis of retinal dystrophy, and
  – The decision for gene therapy is contingent on the test results
• SCNN1A (pseudohypoaldosteronism) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for pseudohypoaldosteronism
• SCNN1B (Liddle syndrome, pseudohypoaldosteronism) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Liddle syndrome, pseudohypoaldosteronism
• SCNN1G (Liddle syndrome, pseudohypoaldosteronism) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Liddle syndrome, pseudohypoaldosteronism
• SLC37A4 (glycogen storage disease, type Ib) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glycogen storage disease, type Ib
• TCF4 (Pitt-Hopkins syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Pitt-Hopkins syndrome
• TSC1 (tuberous sclerosis complex 1) – full gene sequence – The patient has signs or symptoms of tuberous sclerosis complex but a diagnosis cannot be clinically confirmed
• TSC2 (tuberous sclerosis complex 2) – duplication/deletion analysis – The patient has signs or symptoms of tuberous sclerosis complex but a diagnosis cannot be clinically confirmed
• UMOD (glomerulocystic kidney disease with hyperuricemia and isosthenuria) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glomerulocystic kidney disease with hyperuricemia and isosthenuria
• WAS (Wiskott-Aldrich syndrome) – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Wiskott-Aldrich syndrome
Coverage for CPT code 81407 (molecular pathology procedure, Level 8) is limited to the listed services. Reimbursement for code 81407 requires an approved TAR and requires providers to document one of the following on the TAR:

- **ABCC8 (familial hyperinsulinism):**
  - The patient has persistent hyperinsulinemic hypoglycemia of infancy (PHHI) who failed medical therapy, and
  - The patient is under evaluation for surgical intervention

- **AGL (glycogen storage disease type III)** – The patient has clinical features suspicious for, or requires the service as a confirmatory test for glycogen storage disease type III

- **APOB (apolipoprotein B)** – full gene sequence – The patient has clinical suspicion for familial hypercholesterolemia (FH) based on any of the following:
  - Elevated LDL-C level of ≥190mg/dL (4.9 mmol/L) in patients with a negative or unknown family history.
  - Family member with known FH or elevated cholesterol (>240 mg/dL [6.2 mmol/L] in either parent).
  - Personal or family history of xanthomas.
  - Family history of premature coronary heart disease.
  - Family history of sudden premature cardiac death.

- **JAG1 (Alagille syndrome)** – full gene sequence – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Alagille syndrome

- **NOTCH (notch 1)** – full gene sequence – The patient has suspected or confirmed acute lymphoblastic leukemia, and the result of the test will influence the diagnosis, prognosis and/or therapeutic management

- **NPHS1 (congenital Finnish nephrosis)**
  - The patient has clinical diagnosis of steroid-resistant nephritic syndrome (SRNS)/congenital Finnish nephrosis, and
  - Treatment will be contingent on the test results

- **SCN1A** – The patient has clinical features suspicious for, or requires the service as a confirmatory test for Dravet syndrome

- **SPTBN2 (spinocerebellar ataxia)** – The patient has clinical features suspicious for, or requires the service as a confirmatory test for spinocerebellar ataxia
- TSC2 (tuberous sclerosis complex 2) – full gene sequence –
  The patient has signs or symptoms of tuberous sclerosis complex but a diagnosis cannot be clinically confirmed

**Tier 2, Molecular Pathology Procedure, Level 9**

Coverage for CPT code 81408 (molecular pathology procedure, Level 9) is limited to the listed services. Reimbursement for code 81408 requires an approved *Treatment Authorization Request* (TAR) explaining that the following criteria have been met:

- **ITPR1 (spinocerebellar ataxia)** – The patient has clinical features suspicious for, or requires the service as a confirmatory test for spinocerebellar ataxia
- **DMD (dystrophin), full gene analysis**
  - Patient has a clinical diagnosis of dystrophinopathy based on the history, physical examination and elevated creatine kinase (CK) level
  - Result of the DMD (dystrophin) deletion or duplication is negative
| Human Leukocyte Antigen Typing | CPT codes 81370 – 81380, 81382 and 81383 (human leukocyte antigen typing) are reimbursable only with an ICD-10-CM diagnosis in the range of Z94.0 – Z94.9. CPT code 81381 (HLA Class I typing, high resolution, one allele or allele group, each) is only reimbursable with an ICD-10-CM diagnosis of B20, F31.0 – F31.9, G40.001 – G40.919, G50.0, R75, Z01.812, Z21, Z94.0 – Z94.9. |
Providers should refer to the CPT code book for full descriptions of the following codes

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81413</td>
<td>Yes</td>
<td>The required TAR must document a copy of the report of the physician-interpreted 12-lead electrocardiogram (ECG) with pattern consistent with or suspicious for prolonged QT interval. The TAR must also have clinical documentation of one or more of the following: 1. Torsade de pointes in the absence of drugs known to prolong QT interval 2. T-wave alternans 3. Notched T-wave in three leads 4. Syncope 5. Family members with long QT syndrome 6. Sudden death in family members less than 30 years of age without defined cause</td>
<td>Once-in-a-lifetime for any provider. A TAR may override the frequency limit.</td>
</tr>
<tr>
<td>81414</td>
<td>Yes</td>
<td>The required TAR must document a copy of the report of the physician-interpreted 12-lead electrocardiogram (ECG) with pattern consistent with or suspicious for prolonged QT interval. The TAR must also have clinical documentation of one or more of the following: 1. Torsade de pointes in the absence of drugs known to prolong QT interval 2. T-wave alternans 3. Notched T-wave in three leads 4. Syncope 5. Family members with long QT syndrome 6. Sudden death in family members less than 30 years of age without defined cause</td>
<td>Once-in-a-lifetime for any provider. A TAR may override the frequency limit.</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
</tbody>
</table>
| 81420 Fetal chromosomal aneuploidy genomic sequence analysis panel, must include analysis of chromosomes 13, 18, and 21 | Yes          | A TAR with documentation of the following criteria is required:  
  - Patient with singleton gestation only  
  - The patient has an increased risk of aneuploidy due to one or more of the following:  
    - Maternal age 35 years or older at delivery  
    - Fetal ultrasonographic findings indicating an increased risk of aneuploidy  
    - History of a prior pregnancy with a trisomy  
    - Positive test result for aneuploidy, including first trimester, sequential, or integrated screen, or a quadruple screen  
    - Parental balanced Robertsonian translocation with increased risk of fetal trisomy 13 or trisomy 21  
  
  **Concurrent or repeat use of noninvasive prenatal testing (NIPT) during the same pregnancy is not covered.**  
  
  **Note:** Coverage for NIPT for fetal aneuploidy (cell-free fetal DNA testing) does not include screening for microdeletion syndromes, neural tube defect or ventral wall defects.  
  
<p>|                                                                                     |              |                                                                                          | Once per pregnancy |</p>
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81432 | Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes | Yes | A TAR with documentation of one or more the following criteria is required:  
1. An individual from a family member with a known deleterious BRCA mutation; or  
2. Personal history of breast cancer (invasive or ductal carcinoma in situ) plus one of more of the following:  
   - Diagnosed at ≤45 years of age, or  
   - Diagnosed at 46 – 50 years of age with:  
     - An additional breast cancer primary at any age  
     - One or more close blood relatives with breast cancer at any age  
     - One or more close blood relatives with prostate cancer (Gleason score ≥7)  
     - An unknown or limited family history; or  
   - Diagnosed at ≤60 years of age with a triple negative breast cancer; or  
   - Diagnosed at any age with:  
     - One or more close relatives with:  
       - Breast cancer diagnosed at ≤50 years of age;  
       - Ovarian carcinoma; or  
       - Male Breast cancer; or  
       - Metastatic prostate cancer; or  
       - Pancreatic cancer  
     - Two or more additional diagnosis of breast cancer at any age in patient and/or in close blood relatives; or  
   - Ashkenazi Jewish ancestry; or  
3. Personal history of ovarian carcinoma (includes fallopian tube and primary peritoneal cancers); or  
4. Personal history of male breast cancer; or  
5. Personal history of pancreatic cancer, or | Once-in-a-lifetime except with valid TAR override |

(continued on next page)
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81432</td>
<td>Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes</td>
<td>Yes</td>
<td>6. Personal history of metastatic prostate cancer (biopsy-proven and/or with radiographic evidence; includes distant metastasis and regional bed or nodes; not biochemical recurrence); or 7. Personal history of high-grade prostate cancer (Gleason score ≥7) at any age with: • One or more close blood relatives (first, second or third-degree) with ovarian carcinoma, pancreatic cancer or metastatic prostate cancer at any age or breast cancer under 50 years of age; or • Two or more close blood relatives (first, second, or third-degree relatives on the same side of family) with breast or prostate cancer (any grade) at any age; or • Ashkenazi Jewish ancestry; or 8. BRCA1/2 pathogenic/likely pathogenic variant detected by tumor profiling on any tumor type in the absence of germline pathogenic/likely pathogenic variant analysis; or 9. For an individual without history of breast or ovarian cancer, but with one or more first or second-degree blood relative meeting any of the above criteria</td>
<td>Once-in-a-lifetime except with valid TAR override</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>81435 Hereditary colon cancer disorders; genomic sequence analysis panel, must include sequencing of at least 10 genes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030 – Z85.038, Z85.040 – Z85.048, Z85.42 or Z86.010</td>
<td>Once-in-a-lifetime</td>
<td></td>
</tr>
<tr>
<td>81436 Hereditary colon cancer disorders; genomic sequence analysis panel, must include sequencing of at least 5 genes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: C17.0 – C20, C24.0 – C25.9, C54.0 – C54.9, C65.1 – C66.9, C71.0 – C71.9, D23.0 – D23.9, Z80.0, Z80.49, Z85.030 – Z85.038, Z85.040 – Z85.048, Z85.42 or Z86.010</td>
<td>Once-in-a-lifetime</td>
<td></td>
</tr>
<tr>
<td>81439 Inherited cardiomyopathy genomic sequence analysis panel, must include sequencing of at least 5 genes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with ICD-10-CM diagnosis codes: I42.0 – I42.5 or Z82.41 – Z82.49 A TAR may override the required ICD-10-CM diagnosis codes</td>
<td>Once-in-a-lifetime for any provider A TAR may override the frequency limit</td>
<td></td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>81448 Hereditary peripheral neuropathies, genomic sequence analysis panel, must include sequencing of at least 5 neuropathy-related genes</td>
<td>No</td>
<td>One of the following ICD-10-CM diagnosis codes is required on the claim (except with valid TAR): G11.4 or G60.0</td>
<td>Once-in-a-lifetime for any provider</td>
<td></td>
</tr>
<tr>
<td>81455 Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes</td>
<td>Yes</td>
<td>A TAR for CPT code 81455 requires documentation of the following criteria:</td>
<td>Once-in-a-lifetime for any provider except with valid TAR override</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient has either recurrent, relapsed, refractory, metastatic or advanced stages III or IV cancer, and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient either has not been previously tested using the same Next Generation Sequencing (NGS) test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician, and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The decision for additional cancer treatment is contingent on the test results.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81500 Oncology (ovarian), biochemical assays of two proteins</td>
<td>No</td>
<td>Reimbursable for females who meet the following criteria:</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 18 years of age or older</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICD-10-CM diagnosis code R19.09 is required for reimbursement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>------------</td>
<td></td>
</tr>
</tbody>
</table>
| 81503 Oncology (ovarian), biochemical assays of five proteins | No | Reimbursable for females who meet the following criteria:  
- 18 years of age or older  
- Ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist  
CPT code 81503 is reimbursable only when billed in conjunction with at least one of the following ICD-10-CM diagnosis codes:  
D39.10 – D39.12, N83.00 – N83.02, N83.10 – N83.12, N83.201, N83.202, N83.209, N83.291, N83.292, N83.299, R19.00, R19.03 – R19.05, R19.07 or R19.09. | N/A |
| 81507 Fetal aneuploidy (trisomy 21, 18 and 13) DNA sequence analysis of selected regions | Yes | A TAR with documentation of the following criteria is required:  
- Patient with singleton gestation only  
- The patient has an increased risk of aneuploidy due to one or more of the following:  
  - Maternal age 35 years or older at delivery  
  - Fetal ultrasonographic findings indicating an increased risk of aneuploidy  
  - History of a prior pregnancy with a trisomy  
  - Positive test result for aneuploidy, including first trimester, sequential, or integrated screen, or a quadruple screen  
  - Parental balanced Robertsonian translocation with increased risk of fetal trisomy 13 or trisomy 21  
  Concurrent or repeat use of noninvasive prenatal testing (NIPT) during the same pregnancy is not covered.  
Note: Coverage for **NIPT** for fetal aneuploidy (cell-free fetal DNA testing) does not include screening for microdeletion syndromes, neural tube defect or ventral wall defects.  
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81508</td>
<td>Fetal congenital abnormalities, biochemical assays of two proteins</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: O09.00 – O09.73, Z34.00 – Z34.93, Z36.0, Z36.81, or Z36.83 – Z36.89. Reimbursable for females only</td>
<td>N/A</td>
</tr>
<tr>
<td>81509</td>
<td>Fetal congenital abnormalities, biochemical assays of three proteins</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: O09.00 – O09.73, Z34.00 – Z34.93, Z36.0, Z36.81, or Z36.83 – Z36.89. Reimbursable for females only</td>
<td>N/A</td>
</tr>
<tr>
<td>81510</td>
<td>Fetal congenital abnormalities, biochemical assays of three analytes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: O09.00 – O09.73, Z34.00 – Z34.93, Z36.0, Z36.81, or Z36.83 – Z36.89. Reimbursable for females only</td>
<td>N/A</td>
</tr>
<tr>
<td>81511</td>
<td>Fetal congenital abnormalities, biochemical assays of four analytes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: O09.00 – O09.73, Z34.00 – Z34.93, Z36.0, Z36.81, or Z36.83 – Z36.89. Reimbursable for females only</td>
<td>N/A</td>
</tr>
<tr>
<td>81512</td>
<td>Fetal congenital abnormalities, biochemical assays of five analytes</td>
<td>No</td>
<td>Reimbursable only when billed in conjunction with one of the following ICD-10-CM diagnosis codes: O09.00 – O09.73, Z34.00 – Z34.93, Z36.0, Z36.81, or Z36.83 – Z36.89. Reimbursable for females only</td>
<td>N/A</td>
</tr>
<tr>
<td>CPT Code Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
<td>Frequency</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>-----------</td>
<td></td>
</tr>
</tbody>
</table>
| 81518* Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes | Yes | Requires a Treatment Authorization Request (TAR) with documentation of the following criteria:  
- The recipient is estrogen and progesterone receptor (ER/PgR)-positive.  
- The recipient is HER2-receptor negative.  
- The recipient is lymph node negative.  
- The recipient has stage I or stage II breast cancer.  
- The recipient is a candidate for chemotherapy.  
- The assay is used within six months of diagnosis.  
- The recipient is under consideration for adjuvant systemic therapy.  
Use CPT code 81518 when billing for Breast Cancer Index. | Once-in-a-lifetime  
*See note at the end of this table |
| 81519* Oncology (breast), mRNA, gene expression profiling by real time RT-PCR of 21 genes | Yes | Requires a TAR with documentation of the following criteria:  
- The recipient is estrogen and progesterone receptor (ER/PgR)-positive.  
- The recipient is HER2-receptor negative.  
- The recipient is lymph node negative.  
- The recipient has stage I or stage II breast cancer.  
- The recipient is a candidate for chemotherapy.  
- The assay is used within six months of diagnosis.  
- The recipient is under consideration for adjuvant systemic therapy.  
Use CPT code 81519 when billing for Oncotype Dx. | Once-in-a-lifetime*  
*See note at the end of this table |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
</table>
| 81520* Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes | Yes          | Requires a TAR with documentation of the following criteria:  
  - The recipient is estrogen and progesterone receptor (ER/PgR)-positive.  
  - The recipient is HER2-receptor negative.  
  - The recipient is lymph node negative.  
  - The recipient has stage I or stage II breast cancer.  
  - The recipient is a candidate for chemotherapy.  
  - The assay is used within six months of diagnosis.  
  - The recipient is under consideration for adjuvant systemic therapy.  
  Use CPT code 81520 when billing for Prosigna.                                                                                         | Once-in-a-lifetime*                              
|                                            | *See note at the end of this table     |                                                                                                                                                                                                                           | *See note at the end of this table               |
| 81521* Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes | Yes          | Requires a TAR with documentation of the following criteria:  
  - The recipient has high clinical risk per MINDACT categorization.  
  - The recipient is estrogen and progesterone receptor (ER/PgR)-positive.  
  - The recipient is HER2-receptor negative.  
  - The recipient is lymph node negative or lymph node positive.  
  - The recipient is a candidate for chemotherapy.  
  - The assay is used within six months of diagnosis.  
  - The recipient is under consideration for adjuvant systemic therapy.  
  Use CPT code 81521 when billing for MammaPrint.                                                                                         | Once-in-a-lifetime*                              
|                                            | *See note at the end of this table     |                                                                                                                                                                                                                           | *See note at the end of this table               |

As noted in the 2017 ASCO guideline, the Adjuvant! Online website was not functional. As an alternative, clinicians can determine a patient’s clinical risk status by using the printed version of the Adjuvant! Online clinical risk criteria found in the Data Supplement of the MINDACT publication.
### CPT Code Description | TAR Required | TAR and/or Billing Requirements | Frequency
---|---|---|---
81522*  
Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes  | Yes  
Requires a TAR with documentation of the following criteria:  
- The recipient is estrogen and progesterone receptor (ER/PgR)-positive.  
- The recipient is HER2-receptor negative.  
- The recipient is lymph node negative.  
- The recipient has stage I or stage II breast cancer.  
- The recipient is a candidate for chemotherapy.  
- The assay is used within six months of diagnosis.  
- The recipient is under consideration for adjuvant systemic therapy.  
Use CPT 81522 when billing for EndoPredict.  | Once-in-a-lifetime*  
*See note at the end of this table

81528  
Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers  | No  
Reimbursable for recipients 50 – 75 years of age. For recipients outside this age range, providers must submit a TAR documenting medical necessity.  | Once per year  
For recipients requiring additional tests within a year, providers must submit a TAR documenting medical necessity.
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81541 oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score</td>
<td>Yes</td>
<td>The following criteria must be documented on the TAR:</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. For identification of patients with Prostate Cancer who are most likely to benefit from active surveillance or treatment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Coverage is limited to Decipher®, Prolaris® and ProMark. Gene expression profiling for prostate cancer may be billed as follows:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Decipher® Prostate – Use CPT code 81542</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Prolaris® – Use CPT code 81541</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- ProMark – Use CPT code 81599</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• The patient must have one of the following:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Higher volume Grade Group 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Favorable intermediate risk (e.g., Grade Group 2, percentage of positive biopsy scores, 50 percent and no more than on NCCN intermediate-risk factor)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Discordant features in their risk stratification (e.g., palpable mass with Grade Group 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Other features associated with progression while on active surveillance (e.g., high PSA density and certain germline or somatic mutations)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Unfavorable intermediate-risk when considering decisions to proceed with treatment (i.e. add androgen deprivation therapy to radiation)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Result of the test, when considered as a whole with routine clinical factors, is likely to influence the decision to proceed with surveillance or treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(continued on next page)</td>
<td></td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
<td>TAR Required</td>
<td>TAR and/or Billing Requirements</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| 81541    | TAR and/or Billing Requirements | Yes | 2. For post-prostatectomy patients who seek guidance on adjuvant vs. salvage radiation:  
- Coverage is limited to Decipher Genomic Classifier  
- Result of the test, when considered as a whole with routine clinical factors, is likely to affect treatment | Once-in-a-lifetime |
| 81542    | oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score | Yes | See CPT code 81541 for TAR criteria and billing requirements. | Once-in-a-lifetime |
| 81545    | oncology (thyroid), gene expression analysis of 142 genes | Yes | The following criteria must be documented on the TAR:  
1. The patient is under evaluation for thyroid nodule(s)  
2. The cytopathology result from fine needle aspiration is indeterminate, defined as one of the following:  
   - Follicular lesion of undetermined significance (FLUS), Bethesda III, or  
   - Atypia of undetermined significance (AUS), Bethesda III, or  
   - Follicular neoplasm, Bethesda IV.  
3. The diagnostic or treatment strategy will be contingent on test results | Once-in-a-lifetime |
<table>
<thead>
<tr>
<th>CPT Code Description</th>
<th>TAR Required</th>
<th>TAR and/or Billing Requirements</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>81552 Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes</td>
<td>No</td>
<td>An ICD-10-CD diagnosis code from the following ranges must be documented: C69.30 – C69.32 or C69.40 – C69.42</td>
<td>Once-in-a-lifetime</td>
</tr>
<tr>
<td>81596 Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays</td>
<td>No</td>
<td>The following ICD-10-CM code is required on the claim (except with valid TAR): B18.2</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Note:*
These benefits are limited to EndoPredict, Oncotype Dx, Prosigna (PAM50 risk of recurrence score) and Breast Cancer Index. Use CPT code 81518 when billing for Breast Cancer Index. Use CPT code 81519 when billing for Oncotype Dx. Use CPT code 81520 when billing for Prosigna. Use CPT code 81521 when billing for MammaPrint. Use CPT code 81522 when billing for EndoPredict.

These once-in-a-lifetime benefits may be billed for the same recipient and any provider. Providers need an approved TAR and documentation showing that the recipient has a new second primary breast cancer that meets the necessary criteria as listed above to override the once-in-a-lifetime frequency.

Concurrent use of more than one test is not recommended as there is no data to support that ordering multiple assays in an individual patient would be beneficial in guiding treatment decisions.